ZNTL

+ Watchlist + Portfolio

Zentalis Pharmaceuticals, Inc.

GridBrain — Sign in

GridSentinel — Sign in

GridAegis — Sign in

Key Metrics

Previous Close: $3.82
52-Week Range: $1.21 – $6.95
Market Cap: $363.54M
P/E (TTM): —
EPS (TTM): -1.96
Dividend Yield: —

Advanced Metrics

Price/Book: 1.50
PEG Ratio: —
Return on Equity: -66.75%
Return on Assets: -33.15%
Gross Margin: 0.00%
Operating Margin: 0.00%
Profit Margin: 0.00%
Current Ratio: 4.82
Debt/Equity: 0.26
Total Debt: $37.69M
Free Cash Flow: $-79.45M
Revenue Growth: —
Earnings Growth: —
Enterprise Value: $138.30M

ZNTL Income statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Revenue	$0.00	$0.00	$67.42M	$0.00
Research & Development	$172.73M	$189.59M	$167.77M	$107.30M
Selling, General & Admin	$54.55M	$64.35M	$87.11M	$37.72M
Operating Expenses	$227.29M	$253.94M	$254.88M	$145.01M
Operating Income	-$227.29M	-$253.94M	-$187.46M	-$145.01M
EBITDA	-$225.86M	-$252.55M	-$186.17M	-$144.27M
Pretax Income	-$221.30M	-$276.89M	-$165.69M	-$136.62M
Income Tax	-$469.00K	-$601.00K	$177.00K	$442.00K
Net Income	-$236.81M	-$292.19M	-$165.84M	-$137.06M
Diluted EPS	-4.48	-4.47	-2.33	-1.91
Diluted Shares	52.86M	65.41M	71.08M	71.87M

ZNTL Balance Sheet statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Cash & Equivalents	$43.07M	$28.04M	$33.90M	$35.99M
Receivables	$7.04M	$0.00	$5.00M	$0.00
Current Assets	$451.93M	$496.72M	$386.07M	$253.19M
Total Assets	$539.31M	$551.69M	$430.34M	$288.97M
Current Liabilities	$56.65M	$69.37M	$52.73M	$36.56M
Total Debt	$45.17M	$43.15M	$39.58M	$35.70M
Total Liabilities	$105.29M	$114.30M	$93.15M	$72.76M
Retained Earnings	-$596.37M	-$888.56M	-$1.05B	-$1.19B
Shareholders' Equity	$433.80M	$437.28M	$337.19M	$216.20M
Working Capital	$395.29M	$427.35M	$333.34M	$216.63M

ZNTL Cash Flow statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Operating Cash Flow	-$163.75M	-$207.82M	-$170.86M	-$125.25M
Capital Expenditure	-$2.55M	-$583.00K	-$221.00K	—
Free Cash Flow	-$166.30M	-$208.41M	-$171.08M	-$125.25M
Depreciation & Amortisation	$1.43M	$1.39M	$1.29M	$739.00K
Stock-Based Compensation	$46.84M	$54.82M	$67.27M	$20.72M
Investing Cash Flow	-$114.18M	-$44.46M	$176.56M	$131.62M
Financing Cash Flow	$261.04M	$237.30M	$108.00K	-$4.28M
Share Repurchases	—	$0.00	$0.00	-$9.98M
Net Change in Cash	-$16.89M	-$14.98M	$5.81M	$2.09M

ZNTL Income statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Revenue	$0.00	$0.00	$0.00	$0.00	$0.00
Research & Development	$27.25M	$27.61M	$22.95M	$29.49M	$28.72M
Selling, General & Admin	$10.58M	$8.45M	$10.78M	$7.91M	$9.14M
Operating Expenses	$37.83M	$36.06M	$33.73M	$37.39M	$37.85M
Operating Income	-$37.83M	-$36.06M	-$33.73M	-$37.39M	-$37.85M
EBITDA	-$37.56M	-$35.90M	-$33.57M	-$37.24M	-$37.70M
Pretax Income	-$48.28M	-$26.87M	-$26.69M	-$34.77M	-$35.23M
Income Tax	$0.00	$0.00	$0.00	$442.00K	$120.00K
Net Income	-$48.28M	-$26.87M	-$26.69M	-$35.22M	-$35.35M
Diluted EPS	-0.67	-0.37	-0.37	—	-0.50
Diluted Shares	71.68M	71.99M	72.14M	—	70.26M

ZNTL Balance Sheet statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Cash & Equivalents	$41.93M	$37.60M	$39.07M	$35.99M	$31.93M
Receivables	$0.00	$0.00	$0.00	$0.00	—
Current Assets	$342.88M	$311.60M	$288.30M	$253.19M	$218.10M
Total Assets	$384.02M	$351.71M	$327.25M	$288.97M	$253.07M
Current Liabilities	$49.43M	$39.02M	$37.17M	$36.56M	$35.24M
Total Debt	$38.65M	$37.69M	$36.71M	$35.70M	$34.65M
Total Liabilities	$88.64M	$77.21M	$74.38M	$72.76M	$70.39M
Retained Earnings	-$1.10B	-$1.13B	-$1.16B	-$1.19B	-$1.23B
Shareholders' Equity	$295.38M	$274.50M	$252.87M	$216.20M	$182.68M
Working Capital	$293.45M	$272.57M	$251.13M	$216.63M	$182.86M

ZNTL Cash Flow statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Operating Cash Flow	-$32.64M	-$34.71M	-$26.96M	-$30.94M	-$32.96M
Capital Expenditure	—	—	—	—	-$34.00K
Free Cash Flow	-$32.64M	-$34.71M	-$26.96M	-$30.94M	-$32.99M
Depreciation & Amortisation	$262.00K	$160.00K	$160.00K	$157.00K	$151.00K
Stock-Based Compensation	$6.49M	$6.29M	$4.83M	$3.12M	$3.20M
Investing Cash Flow	$40.48M	$30.38M	$28.32M	$32.45M	$30.01M
Financing Cash Flow	$189.00K	$0.00	$115.00K	-$4.59M	-$1.12M
Net Change in Cash	$8.03M	-$4.33M	$1.47M	-$3.08M	-$4.07M

Market Snapshot

About

Zentalis Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics for cancer treatment. The company targets genetically defined cancers with precision medicine approaches. Zentalis has multiple oncology programs in clinical development.